Literature DB >> 9574449

Which urinary proteins are decreased after angiotensin converting--enzyme inhibition?

E Guidi1, A Giglioni, M G Cozzi, E E Minetti.   

Abstract

It is believed that angiotensin converting-enzyme (ACE) inhibitors lower proteinuria by acting on glomerular hemodynamics. This hypothesis predicts that the urinary excretion of a tubular protein should be unaffected by ACE inhibition. In the present study we have compared the excretion of albumin and Tamm-Horsfall Glycoprotein (THGP), a protein secreted only by renal tubules, before and after ACE inhibition. Urinary protein excretion was measured with the Phast System, a method based on SDS polyacrylamide gel electrophoresis followed by silver staining, in 15 essential hypertensives, after at least 4 weeks of wash-out from any drug and after 2 months of ACE inhibition with oral Quinapril. After 2 months of ACE inhibition, blood pressure (BP), body weight, urinary output, heart rate, plasma glucose, plasma and urinary creatinine, urate and electrolytes, and creatinine clearance, were not different from baseline values. Plasma ACE activity decreased from 76 +/- 7 to 10 +/- 4 U/mL (mean +/- SEM, 2 tails paired t test, p = 0.0001). Both albumin and THP urinary excretions decreased from 51 +/- 6 to 43 +/- 4 mg/ 24 h (p = 0.05) and from 19 +/- 3 to 12 +/- 1 mg/24 h (p = 0.02), respectively. This unexpected result suggests that ACE inhibitors may act also at the level of renal tubular cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574449     DOI: 10.3109/08860229809045108

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

Review 1.  Uromodulin in kidney injury: an instigator, bystander, or protector?

Authors:  Tarek M El-Achkar; Xue-Ru Wu
Journal:  Am J Kidney Dis       Date:  2012-01-23       Impact factor: 8.860

2.  Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone.

Authors:  A J Bleyer; M Zivná; H Hulková; K Hodanová; P Vyletal; J Sikora; J Zivný; J Sovová; T C Hart; J N Adams; M Elleder; K Kapp; R Haws; L D Cornell; S Kmoch; P S Hart
Journal:  Clin Nephrol       Date:  2010-12       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.